(414d) Charge Reversal Liposomes for Cancer Nuclear Drug Delivery | AIChE

Other Sites & Tools

Technical Groups

(414d) Charge Reversal Liposomes for Cancer Nuclear Drug Delivery

Authors 

Ma, X. - Presenter, University of Wyoming
Zhou, Z. - Presenter, University of Wyoming
Zhang, B. - Presenter, University of Wyoming
Tang, J. - Presenter, Zhejiang University
Fan, M. - Presenter, University of Wyoming
Tang, H. - Presenter, Department of Chemical and Petroleum Engineering, University of Wyoming
Shen, Y. - Presenter, Zhejiang University
Radosz, M. - Presenter, Department of Chemical and Petroleum Engineering, University of Wyoming
Van Kirk, E. - Presenter, University of Wyoming
Murdoch, W. - Presenter, University of Wyoming


Cationic liposomes have fast cellular uptakes but nonspecific cellular uptakes and are toxic, immediately clear out from the blood, accumulate in lung, Herein, we report liposomes that can undergo negative-to-positive charge-reversal triggered by the solid tumor extracellular- or lysosomal (4-5) acidity for nuclear drug delivery. Doxorubicin loaded in the liposomes is more cytotoxic to tumor cells than the free drug. The liposomes have a long blood circulation time and thus are good for in vivo cancer drug delivery.

More Conference Links